Lumena raises $23M to advance liver-disease drug

05/9/2013 | American City Business Journals

A Series A funding round has brought in $23 million to Lumena Pharmaceuticals, a California-based biotech firm founded by Pappas Ventures. Proceeds will go toward the development of the company's lead drug candidate for cholestatic liver disease. Lumena plans to conduct midstage trials of the drug in adults with primary biliary cirrhosis and in children with alagille syndrome and progressive familial intrahepatic cholestasis.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN